250 related articles for article (PubMed ID: 16776743)
1. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.
Wyne KL
Diabetes Obes Metab; 2006 Jul; 8(4):365-80. PubMed ID: 16776743
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
Nesto R
Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
Viberti G
J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
Rosenberg DE; Jabbour SA; Goldstein BJ
Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
[TBL] [Abstract][Full Text] [Related]
5. Management issues in the metabolic syndrome.
Deedwania PC; Gupta R
J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
[TBL] [Abstract][Full Text] [Related]
6. Potential cardiovascular benefits of insulin sensitizers.
Kunhiraman BP; Jawa A; Fonseca VA
Endocrinol Metab Clin North Am; 2005 Mar; 34(1):117-35. PubMed ID: 15752925
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes.
Dandona P; Ghanim H; Chaudhuri A; Mohanty P
J Diabetes Complications; 2008; 22(1):62-75. PubMed ID: 18191079
[TBL] [Abstract][Full Text] [Related]
9. The metabolic syndrome - an ongoing story.
Duvnjak L; Duvnjak M
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():19-24. PubMed ID: 20388942
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis.
Tkác I
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S2-9. PubMed ID: 15955370
[TBL] [Abstract][Full Text] [Related]
11. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome.
Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome and the menopause.
Kaaja RJ
Menopause Int; 2008 Mar; 14(1):21-5. PubMed ID: 18380957
[TBL] [Abstract][Full Text] [Related]
14. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
Meigs JB; Rutter MK; Sullivan LM; Fox CS; D'Agostino RB; Wilson PW
Diabetes Care; 2007 May; 30(5):1219-25. PubMed ID: 17259468
[TBL] [Abstract][Full Text] [Related]
15. Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women.
Gaspard U
Maturitas; 2009 Apr; 62(4):362-5. PubMed ID: 19131194
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.
Deedwania PC; Schmieder R
J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S12-8. PubMed ID: 16986230
[TBL] [Abstract][Full Text] [Related]
17. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Yamagishi S; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones, insulin resistance and obesity: Finding a balance.
Wilding J
Int J Clin Pract; 2006 Oct; 60(10):1272-80. PubMed ID: 16981971
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome: are we at risk?
Paudel B
Nepal Med Coll J; 2007 Sep; 9(3):204-11. PubMed ID: 18092442
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events.
Zarich SW
Rev Cardiovasc Med; 2005; 6(4):194-205. PubMed ID: 16379015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
